EUVIMEDEUVIMED entdecken
Crossref

Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol

Inès Rezzoug, Kenza Ouacel, Thomas Droit, Sarah Ronsin, Rémy A Bonnin, Agnès B Jousset, Lena Latour, Laurent Dortet iD, Cécile Emeraud

Journal of Antimicrobial Chemotherapy · 02.12.2025 · 80 (12) · 3297-3305

DOI: 10.1093/jac/dkaf364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 28.10.2025. Verfasst von Inès Rezzoug und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, beta-Lactamases, Cephalosporins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: ADVANZ PHARMA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Carbapenem-resistant Enterobacterales (CRE) that do not produce carbapenemases (non-CPE) are increasingly reported worldwide and represent a major therapeutic challenge. These strains are typically resistant to carbapenems due to the combined effects of ESBL and/or AmpC production and reduced outer membrane permeability. However, data on their susceptibility to new antibiotics and β-lactam/β-lactamase inhibitor (BL/BLI) combinations remain limited. This study aimed to evaluate the in vitro activity of new antibiotics and BL/BLI combinations against CR non-CPE isolates.

Methods

MICs of ceftazidime–avibactam, cefepime–enmetazobactam, cefepime–taniborbactam, cefepime–zidebactam, imipenem–relebactam, meropenem–vaborbactam, aztreonam–avibactam, and cefiderocol were determined by the broth microdilution for 151 CR non-CPE isolates collected between 2024 and January 2025 at the French National Reference Center. The collection included ESBL producers (n = 33), AmpC producers (n = 79), and ESBL/AmpC co-producers (n = 29).

Results

Overall susceptibility rates were as follows: cefepime–zidebactam (97.4%), aztreonam–avibactam (92.7%), ceftazidime–avibactam (91.4%), meropenem–vaborbactam (91.3%), imipenem–relebactam (88.7%), cefiderocol (86.8%), cefepime–taniborbactam (82.1%), and cefepime–enmetazobactam (68.9%). Susceptibility varied according to the resistance mechanisms. Among ESBL producers, CTX-M-33-producing strains exhibited higher MICs than CTX-M-15 producers. Among AmpC producers, no specific high-risk AmpC type was associated with higher MICs, but Klebsiella aerogenes isolates exposed higher MICs than Enterobacter cloacae complex isolates.

Conclusions

CR non-CPE exhibit heterogeneous resistance profiles, especially in ESBL/AmpC co-producers and CTX-M-33-producing isolates. While cefepime–zidebactam, imipenem–relebactam, and cefiderocol were the most active agents, susceptibility testing remains essential to guide therapy in this emerging and neglected bacterial group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesCephalosporinsBacterial ProteinsEnterobacteriaceaeMicrobial Sensitivity TestsHumansCefiderocolDrug CombinationsAzabicyclo CompoundsEnterobacteriaceae InfectionsCefepimeCarbapenem-Resistant EnterobacteriaceaeCeftazidimeImipenemCyclooctanesMeropenemBorinic AcidsCarboxylic AcidsPiperidines

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesCephalosporinsCefiderocolDrug CombinationsAzabicyclo CompoundsBacterial Proteinsavibactam, ceftazidime drug combinationAmpC beta-lactamases

Autor:innen und Institutionen

  • Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
  • INSERM UMR 1184, Paris-Saclay University, Le Kremlin-Bicêtre, France.
  • French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France.
  • Paris-Saclay University, Faculty of Medicine, Le Kremlin-Bicêtre, France.

ORCID-Profile: Laurent Dortet

Förderung

  • ADVANZ PHARMA

Zitieren

APA

Rezzoug, I., Ouacel, K., Droit, T., Ronsin, S., Bonnin, R. A., Jousset, A. B., Latour, L., Dortet, L., & Emeraud, C. (2025). Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol. Journal of Antimicrobial Chemotherapy, 80(12), 3297-3305. https://doi.org/10.1093/jac/dkaf364

Vancouver

Rezzoug I, Ouacel K, Droit T, Ronsin S, Bonnin RA, Jousset AB, et al. Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol. Journal of Antimicrobial Chemotherapy. 2025;80(12):3297-3305. doi:10.1093/jac/dkaf364

BibTeX
@article{Rezzoug2025,
  author = {Rezzoug, Inès and Ouacel, Kenza and Droit, Thomas and Ronsin, Sarah and Bonnin, Rémy A and Jousset, Agnès B and Latour, Lena and Dortet, Laurent and Emeraud, Cécile},
  title = {Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {12},
  pages = {3297--3305},
  doi = {10.1093/jac/dkaf364}
}
Kostenlos starten →